Cotinga Pharmaceuticals Inc COTQF

new member Coti shareholder April 2014

[Cotitwo]

Hi
I attended the shareholder meeting which had about 30 investors in attendence  Alison spoke and answered many questions for 90 plus minutes and had the rooms attention  No one left
It was an excellent presentation and even though our stock price is ridiculously under valued i think the future looks very bright
The Gynecological study is complete and declared it a sucess 24 women took part in the study and results will be released when complete  they were very up beat about it
She also said they are now ready to start Head and Neck human trials at MDACC in Houston
The FDA is allowing them to start at 1 mg instead of 0.25 mgs which saves us a lot of time and money  She explained that H and N is a Singular cancer which makes a much more attractive canidate for the study where as the women in the gynecological study were in stage 4 and there initial cancer had metastasized which led to a number of women dropping out
Another important fact is the patients can now be screened before they are accepted which gives them the opourtunity to choose the ideal patient for the study (mutant p 53 gene)
We didnt have that opourtunity in the G study
She talked about Coti 219 The drug is being manufactured now and they will be starting there Two species toxicity study which is needed to complete there IND (investigative new drug) for the FDA
Coti 219 attacks the Big cancers Colon (166,000 a year U S alone) pancreatic and lung caner
Big pharma has there eyes on this  She mentioned Bayer as one of the companies and depending on the results of the 2 species study they could jump in before the human trials start
Talked finacing  Want to raise 2.5 million which the board will take at least 10 % of that
Priced at 1.25 with one full warrant at 2.00 expiry one year  There is an Exceleration clause as well  Financing closes on or around Sept 7
Thats it for now
Cheers